<DOC>
	<DOC>NCT03052127</DOC>
	<brief_summary>The primary objective is to assess the safety, immunogenicity and preliminary efficacy of a single treatment of one of two dose levels of Light-activated AU-011 for the treatment of subjects with primary choroidal melanoma.</brief_summary>
	<brief_title>Phase 1B Study in Subjects With Small to Medium Primary Choroidal Melanoma</brief_title>
	<detailed_description>This is a phase 1B open-label, single ascending dose clinical trial designed to evaluate the safety of two dose levels of Light-activated AU-011 for the treatment of subjects with small to medium primary choroidal melanoma. Throughout the study, subjects will be monitored through medical and ophthalmic assessments. Subjects will be followed for a total of 2 years.</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Diagnosis of uveal melanoma Have known contraindications or sensitivities to the study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Uveal melanoma</keyword>
	<keyword>Eye cancer</keyword>
	<keyword>Ocular melanoma</keyword>
	<keyword>Choroidal melanoma</keyword>
</DOC>